Literature DB >> 25971646

FISHing Tips: What Every Clinician Should Know About 1p19q Analysis in Gliomas Using Fluorescence in situ Hybridisation.

M B Pinkham1, N Telford2, G A Whitfield3, R J Colaco4, F O'Neill2, C A McBain4.   

Abstract

1p19q co-deletion is a chromosomal alteration associated with primary brain tumours of oligodendroglial histology. It is an established predictive and prognostic biomarker that informs whether patients are offered radiotherapy, chemotherapy or both. In the near future, 1p19q co-deletion status may also be incorporated into the reclassification of gliomas. Analysis is commonly carried out using fluorescence in situ hybridisation (FISH) because it is a reliable and validated laboratory technique. The result is generally considered to be dichotomous (1p19q co-deletion present or absent), but there are subtleties in interpretation that are of clinical relevance. Separate centres may interpret certain chromosome deletion patterns differently. Pivotal trials in mixed and pure anaplastic oligodendrogliomas have used slightly different FISH probe ratios as the cut-off for chromosome deletion. Here we review the clinical implications of this variability and review the process of 1p19q co-deletion assessment using FISH in gliomas from a clinician's perspective. We also consider common alternative methods of analysis.
Copyright © 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  1p19q; fluorescence in situ hybridisation (FISH); glioma; oligodendroglioma; polysomy; review

Mesh:

Year:  2015        PMID: 25971646     DOI: 10.1016/j.clon.2015.04.008

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  8 in total

Review 1.  Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Authors:  Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Sebastian Brandner; Luke Vale; Julian Pt Higgins; Kathreena M Kurian
Journal:  Cochrane Database Syst Rev       Date:  2022-03-02

2.  Frequency of false-positive FISH 1p/19q codeletion in adult diffuse astrocytic gliomas.

Authors:  Matthew K Ball; Thomas M Kollmeyer; Corinne E Praska; Michelle L McKenna; Caterina Giannini; Aditya Raghunathan; Mark E Jentoft; Daniel H Lachance; Benjamin R Kipp; Robert B Jenkins; Cristiane M Ida
Journal:  Neurooncol Adv       Date:  2020-08-27

3.  Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization.

Authors:  Jongmin Sim; Do-Hyun Nam; Yuil Kim; In-Hee Lee; Jung Won Choi; Jason K Sa; Yeon-Lim Suh
Journal:  Med Oncol       Date:  2018-03-29       Impact factor: 3.064

4.  FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas.

Authors:  Radwa Sharaf; Dean C Pavlick; Garrett M Frampton; Maureen Cooper; Jacqueline Jenkins; Natalie Danziger; James Haberberger; Brian M Alexander; Timothy Cloughesy; William H Yong; Linda M Liau; Phioanh L Nghiemphu; Matthew Ji; Albert Lai; Shakti H Ramkissoon; Lee A Albacker
Journal:  Neurooncol Adv       Date:  2021-02-04

5.  IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis.

Authors:  Zuzana Sporikova; Rastislav Slavkovsky; Lucie Tuckova; Ondrej Kalita; Magdalena Megova Houdova; Jiri Ehrmann; Marian Hajduch; Lumir Hrabalek; Miroslav Vaverka
Journal:  Appl Immunohistochem Mol Morphol       Date:  2022-03-01

6.  Recurrent oligodendroglioma with changed 1p/19q status.

Authors:  Valeria Barresi; Andrea Mafficini; Martina Calicchia; Maria Liliana Piredda; Angelo Musumeci; Claudio Ghimenton; Aldo Scarpa
Journal:  Neuropathology       Date:  2022-02-10       Impact factor: 2.076

Review 7.  Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.

Authors:  Sebastian Brandner; Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Neuropathol Appl Neurobiol       Date:  2022-03-03       Impact factor: 6.250

8.  H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.

Authors:  Aldo Scarpa; Valeria Barresi; Serena Ammendola; Nicolò Caldonazzi; Michele Simbolo; Maria Liliana Piredda; Matteo Brunelli; Pietro Luigi Poliani; Giampietro Pinna; Francesco Sala; Claudio Ghimenton
Journal:  Virchows Arch       Date:  2021-06-24       Impact factor: 4.535

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.